public access repository recombinant dna sources (PromoCell)
PromoCell is a verified supplier 
PromoCell manufactures this product 
97
Structured Review
PromoCell
public access repository recombinant dna sources
Public Access Repository Recombinant Dna Sources, supplied by PromoCell, used in various techniques. Bioz Stars score: 97/100, based on 306 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/public+access+repository+recombinant+dna+sources/Normal+Human+Dermal+Fibroblasts/pm37995437-11-241-239
Average 97 stars, based on 306 article reviews
Public Access Repository Recombinant Dna Sources, supplied by PromoCell, used in various techniques. Bioz Stars score: 97/100, based on 306 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/public+access+repository+recombinant+dna+sources/Normal+Human+Dermal+Fibroblasts/pm37995437-11-241-239
Average 97 stars, based on 306 article reviews
public access repository recombinant dna sources - by Bioz Stars,
2026-10
97/100 stars
Images
Related Articles
Cell Culture:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Modification:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Knock-Out:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial CRISPR:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Plasmid Preparation:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Transfection:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Electroporation:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Sequencing:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Activity Assay:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Polymerase Chain Reaction:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Selection:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial Recombinant:Article Title: Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy. Article Snippet: Unique stem cell line identifier JMUi001-A-4 Alternative name(s) of stem cell line JUP-KO Institution Comprehensive Heart Failure Center and Medicine I, University Hospital Würzburg, Würzburg, Germany Contact information of the reported cell line distributor Brenda Gerull, Gerull_b@ukw.de Type of cell line iPSC Origin Human Additional origin info Age: 6 years Sex: male Cell Source Dermal fibroblasts Method of reprogramming JMUi001-A via lentivirus Clonality Clonal Evidence of the reprogramming transgene loss (including genomic copy if applicable) N/A The cell culture system used N/A Type of the Genetic Modification ACM related biallelic knock-out in iPSCs Associated disease Naxos disease (MIM #601214) and arrhyhtmogenic cardiomyopathy (MIM #611528) Gene/locus JUP, 17q21 (MIM #173325) harboring a JUP-KO: M23410.1 (JUP): c. [58_68del11];[67delG] (continued on next column) (continued ) Unique stem cell line identifier JMUi001-A-4 Method of modification / usercustomisable nuclease (UCN) used, the resource used for design optimisation CRISPR/Cas9 User-customisable nuclease (UCN) delivery method Encoding plasmid transfection via electroporation All double-stranded DNA genetic material molecules introduced into the cells Plasmid PX459 V2.0 Analysis of the nuclease-targeted allele status Sanger sequencing of targeted alleles Method of the off-target nuclease activity prediction and surveillance Targeted off-target site PCR Descriptive name of the transgene N/A Eukaryotic selective agent resistance cassettes (including inducible, gene/ cell type-specific) Positive puromycin selection Inducible/constitutive expression system details N/A Date archived/stock creation date N/A Cell line repository/bank https://hpscreg.eu/cell-line/JM Ui001-A-4 Ethical/GMO work approvals Original dermal fibroblasts of JMUi001- A were obtained by a commercial |